Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia

Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia

Abstract L-DOPA administration is the primary treatment for Parkinson’s disease (PD) but long-term administration is usually accompanied by hyperkinetic side-effects called L-DOPA-induced dyskinesia (LID). Signaling neuropeptides of the basal ganglia are affected in LID and changes in the expression...

Descripció completa

Dades bibliogràfiques
Autors principals: Heather Hulme, Elva Fridjonsdottir, Theodosia Vallianatou, Reza Shariatgorji, Anna Nilsson, Qin Li, Erwan Bezard, Per E. Andrén
Format: Article
Idioma:English
Publicat: Nature Portfolio 2022-04-01
Col·lecció:npj Parkinson's Disease
Accés en línia:https://doi.org/10.1038/s41531-022-00299-7

Internet

https://doi.org/10.1038/s41531-022-00299-7

Ítems similars